Company news

Swedish Orphan Biovitrum AB news in 2025

Swedish Orphan Biovitrum AB's news releases, calls and decks from 2025, newest first.

View company

Save the Date: Sobi to host a Capital Markets Day on 18 February 2026

December 18, 2025

Sobi to acquire Arthrosi Therapeutics, strengthening pipeline for the potential treatment of gout

December 15, 2025

Viva Biotech's invested and incubated company, Arthrosi, has entered into an acquisition agreement with Sobi for a total transaction value of up to US$1.5 billion.

December 15, 2025

Sobi Receives Positive CHMP Opinion for Aspaveli® (pegcetacoplan) for the Treatment of C3G and Primary IC-MPGN

December 12, 2025

Sobi to Showcase Scientific advances and Commitment to Haematology at ASH 2025

December 5, 2025

The New England Journal of Medicine Publishes Positive Phase 3 VALIANT Results of pegcetacoplan for C3G and Primary IC-MPGN

December 4, 2025

Clinically meaningful pivotal study results for olezarsen in sHTG presented as a late breaker at AHA Scientific Sessions

November 8, 2025

Sobi to present New One-Year Data on pegcetacoplan's efficacy in C3G and primary IC-MPGN and new outcome data on NASP at ASN Kidney Week

November 5, 2025

Data presented at ACR Convergence 2025 highlight Sobi’s commitment to advancing care across rare and underserved inflammatory conditions

October 25, 2025

Sobi showcases new data across rare inflammatory conditions at ACR 2025

October 24, 2025

Change in the Sobi Board of Directors

October 21, 2025

Sobi Q3 2025 report: Accelerated growth and portfolio momentum

October 20, 2025

Sobi announces revised full year outlook and advances publication of the Q3 2025 financial report

October 19, 2025

Invitation: Sobi's Q3 2025 report

October 8, 2025

Sobi Selects Kinaxis to Accelerate Access to Life-Changing Treatments

October 2, 2025

New number of shares and votes in Sobi

September 30, 2025

Tryngolza ® (olezarsen) approved in the European Union for familial chylomicronemia syndrome (FCS)

September 19, 2025

Invitation: Sobi's NASP and Uncontrolled Gout call and webcast

September 10, 2025

FDA Accepts Biologics License Application for Sobi's NASP for Patients with Uncontrolled Gout

September 10, 2025

Sobi has completed issues of class C shares

August 21, 2025

TRYNGOLZA® (olezarsen) recommended for EU approval by CHMP for familial chylomicronemia syndrome (FCS)

July 25, 2025

Sobi publishes Q2 2025 report: Continued strong portfolio and pipeline momentum

July 16, 2025

The Board of Directors of Sobi exercises authorisation for repurchase of shares for the purpose of securing the company's commitments under incentive programmes

July 15, 2025

Invitation: Sobi's Q2 report

July 2, 2025

Sobi to amend existing agreement with Apellis for ex-U.S. royalties of Aspaveli® (systemic pegcetacoplan)

July 1, 2025

FDA approves Gamifant® (emapalumab-lzsg) as first-ever treatment for adults and children with Macrophage Activation Syndrome in Still's disease

June 27, 2025

Sobi will showcase extensive research and clinical outcomes at ISTH 2025

June 20, 2025

Sobi share new clinical data across multiple hematologic diseases at EHA 2025

June 12, 2025

Sobi and Apellis: Aspaveli®/Empaveli® Demonstrates Sustained One-Year Efficacy in Phase 3 Study for Rare Kidney Diseases

June 6, 2025

Sobi Showcases Breadth of data in C3G/primary IC-MPGN at ERA 2025

June 4, 2025

Invitation: Sobi's Aspaveli® - 52-week Phase 3 VALIANT data in nephrology

June 3, 2025

Sobi to share new clinical data and research at EULAR 2025

May 28, 2025

Sobi publishes Q1 2025 report: Portfolio continues to deliver

April 29, 2025

Sobi presents clinical data at WFH 2025 Comprehensive Care Summit

April 23, 2025

Calls in 2025

Decks in 2025